⚠ Evidence warning: Clinical trials or other evidence do not support the claims that black seed with honey shortens cough and bronchitis, and that steam or nasal use clears airways. This page keeps it as a report of what people, websites or other media say.

Black Seed for Asthma and Respiratory Function

Asthma and Respiratory — scientific infographic poster

Asthma is the most clinically studied respiratory application of black seed. Three small randomized controlled trials — Boskabady et al. 2007 (Iran, a boiled seed extract), Salem et al. 2017 (Saudi Arabia, partly controlled adult asthma, ground whole seed) and Koshak et al. 2017 (Saudi Arabia, oil capsules) — gave black seed on top of usual asthma treatment and reported better asthma symptoms or control scores, with some lung function gains such as FEV1 (forced expiratory volume in one second) in the first two. A 2017 literature review called the evidence “scanty” and said it is often based on poorly characterised preparations. The proposed mechanism has three parts: nigellone and thymoquinone inhibit histamine release from mast cells (in laboratory rat cells), a seed extract relaxes the airway smooth muscle, and thymoquinone reduces airway inflammation via NF-kB inhibition. The Middle Eastern medical tradition of using black seed for cough, bronchitis, and chest congestion is a report of long use; no trial of those uses was found.


Table of Contents

  1. Middle Eastern Respiratory Tradition
  2. The Boskabady 2007 Asthma Randomized Controlled Trial
  3. The Salem 2017 Saudi Asthma Randomized Controlled Trial
  4. The Koshak 2017 Oil Capsule Trial
  5. Thymoquinone, Mast Cells, and Histamine Release Inhibition
  6. Direct Bronchodilation Mechanism
  7. Reduction of Airway Inflammation (NF-kB Pathway)
  8. Allergic Rhinitis Evidence
  9. Cough, Bronchitis, and Acute Respiratory Tract Use
  10. Chronic Obstructive Pulmonary Disease Evidence and Limitations
  11. Doses in the Trials and in Traditional Use
  12. Cautions and Limits
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Middle Eastern Respiratory Tradition

The traditional Middle Eastern and South Asian use of black seed for respiratory complaints stretches back to at least the time of Avicenna (Ibn Sina, 980–1037 CE), whose Canon of Medicine recommends black seed for cough, breathing difficulty, fever, and chest tightness. The traditional preparations include:

Modern pharmacology has explained why these preparations might genuinely have worked. Thymoquinone is volatile enough to be carried in steam, and inhalation delivers it directly to the bronchial mucosa where its anti-inflammatory and mast-cell-stabilizing effects are immediately relevant. Honey is itself mildly anti-inflammatory and has demonstrated benefit for acute cough in children (per multiple controlled trials). The traditional combination is mechanistically sound, not folk superstition.

Back to Table of Contents

The Boskabady 2007 Asthma Randomized Controlled Trial

The Boskabady 2007 trial published in Fundamental & Clinical Pharmacology is the earliest of the three trials on this page. The authors call it a phase I study. The design:

Results favored the black seed arm:

The Boskabady 2007 limitations were primarily sample size (29 patients) and a single dose, so it cannot show a dose-response. The authors said the results generally suggest a preventive effect and warrant further research. A 2017 literature review later counted 14 animal or cell studies and 7 clinical studies of black seed in asthma, and said the evidence “remains scanty” and is often based on poorly characterised preparations.

Back to Table of Contents

The Salem 2017 Saudi Asthma Randomized Controlled Trial

The Salem et al. 2017 trial was published in the Annals of Saudi Medicine. Design:

Results:

The trial was placebo-controlled and the patients remained on their standard controller therapy throughout — a design that studies adding black seed rather than replacing medicine. The authors concluded that it “improves some measures of pulmonary function and inflammation in partly controlled asthma”; many of the changes were measured against baseline, and no lavage or sputum samples were taken.

Back to Table of Contents

The Koshak 2017 Oil Capsule Trial

In this double-blind trial in Saudi Arabia, published in Phytotherapy Research, 80 adults with asthma took black seed oil capsules 500 mg or placebo twice daily for 4 weeks on top of their usual treatment. Ten people in each group withdrew.

The authors said future studies need longer follow-up across several centres.

Back to Table of Contents

Thymoquinone, Mast Cells, and Histamine Release Inhibition

The cornerstone mechanism for black seed in asthma is mast cell stabilization — the inhibition of histamine and other inflammatory mediator release from mast cells in airway tissue. Mast cells are sentinel immune cells densely populated in airway mucosa, gastrointestinal mucosa, skin, and blood vessel walls. When activated by immunoglobulin E-allergen crosslinking on their surface, mast cells release granules containing histamine, tryptase, chymase, leukotrienes, prostaglandin D2, and platelet-activating factor — the cocktail responsible for the symptoms of allergic asthma, allergic rhinitis, urticaria, and anaphylaxis.

Cromolyn sodium was the first pharmaceutical mast cell stabilizer, developed in the 1960s based on khellin from Ammi visnaga (a Middle Eastern medicinal plant). Cromolyn works by stabilizing the mast cell membrane and preventing degranulation in response to allergen challenge.

Both thymoquinone and nigellone (the carbonyl polymer of thymoquinone formed during black seed oil aging) appear to function as natural mast cell stabilizers via a similar mechanism. A 1993 laboratory study on rat peritoneal mast cells found that nigellone in relatively low concentrations was very effective at inhibiting histamine release triggered by antigen in sensitized cells and by other agents; no work on human mast cells was read for this page. Animal reports describe reduced histamine and tryptase in lung washings from asthmatic-model animals after black seed treatment.

This is the proposed reason black seed could help asthma patients alongside their existing inhaler therapy: it would address the upstream mast cell degranulation that drives the entire allergic-asthma cascade, complementing but not duplicating the action of beta-2 agonists (which dilate already-constricted airways) or inhaled corticosteroids (which broadly suppress airway inflammation downstream of mast cell activation).

For more on mast cell stabilization broadly, including the related condition of mast cell activation syndrome (MCAS), see Mast Cell Activation Syndrome (MCAS) and Natural Mast Cell Stabilizers.

Back to Table of Contents

Direct Bronchodilation Mechanism

In addition to upstream mast cell stabilization, thymoquinone has demonstrated direct bronchodilator activity on airway smooth muscle in isolated tissue preparations. Tracheal rings from guinea pigs and rats, when pre-contracted with methacholine or histamine, show measurable relaxation upon thymoquinone application — an effect that is independent of beta-2 adrenergic receptors (because pretreatment with beta-2 blockers does not abolish the bronchodilation).

Reduced intracellular calcium release from the sarcoplasmic reticulum and possibly direct potassium channel opening have been proposed. Calcium channel blockade has been proposed too, but the same Iranian research group tested it on guinea pig trachea with seed extracts and concluded that it does not contribute to the relaxant effect.

There is one human measurement. In 15 asthma patients, boiled extract at 50 and 100 mg/kg raised lung function tests from 30 minutes to about 150 minutes after a dose. Most measures rose less than with theophylline, and the effect was significantly less than salbutamol at 30 minutes.

The weaker effect and 30-minute onset mean black seed extract does not match a rescue inhaler in an acute asthma attack. Practitioners propose that daily use adds a background bronchodilator tone to the controller medicine's anti-inflammatory effect.

The combined effect of (mast cell stabilization preventing future bronchoconstrictor mediator release) + (direct bronchodilation reducing baseline airway tone) + (anti-inflammatory effect reducing chronic airway inflammation) is the proposed case for black seed in asthma.

Back to Table of Contents

Reduction of Airway Inflammation (NF-kB Pathway)

Chronic eosinophilic airway inflammation is the underlying pathology of allergic asthma. Eosinophils accumulate in the airway mucosa, degranulate to release major basic protein and eosinophil cationic protein (which damage epithelium), and perpetuate a cycle of inflammation that drives remodeling of the airway wall over years — smooth muscle hypertrophy, basement membrane thickening, mucus gland hyperplasia — producing the fixed component of airflow obstruction in long-standing asthma.

Thymoquinone's NF-kB inhibition addresses this inflammation upstream. NF-kB drives the expression of cytokines (IL-4, IL-5, IL-13, IL-25, IL-33, TSLP) that recruit and activate eosinophils. By suppressing NF-kB activation, thymoquinone is proposed to reduce eosinophil recruitment to airway tissue and eosinophil degranulation. The Koshak 2017 trial measured the related blood marker: eosinophils fell by 50 cells/µL on oil against a rise of 15 on placebo (p = 0.013), alongside better control scores but no significant change in FEV1.

This is the same molecular mechanism that drives the benefit seen in rheumatoid arthritis (where NF-kB-driven synovial inflammation is the target) and in type 2 diabetes (where NF-kB-driven adipose tissue inflammation drives insulin resistance). One target, three clinical applications.

Back to Table of Contents

Allergic Rhinitis Evidence

Allergic rhinitis (hay fever) shares the same immunoglobulin E / mast cell / histamine mechanism as allergic asthma, but affects the upper rather than lower airway. Given the mast cell stabilization effect of thymoquinone, allergic rhinitis is a logical target for black seed therapy.

Several controlled trials have documented benefit:

The clinical implication is that patients suffering both allergic asthma and allergic rhinitis (a common combination — the "unified airway" hypothesis) may get integrated benefit across both conditions from a single black seed regimen. This is parallel to what oral antihistamines and to a lesser extent inhaled corticosteroids accomplish, but with a different mechanism that may be useful for patients who do not tolerate or do not fully respond to conventional therapy.

For the broader allergy management framework, see Allergy & Immunology and Allergic Rhinitis.

Back to Table of Contents

Cough, Bronchitis, and Acute Respiratory Tract Use

For acute respiratory tract irritation — cough, bronchitis, post-viral airway hyperreactivity — black seed has a substantial folk-tradition base and limited but supportive modern data. A 2018 comparative review of cough-suppressing (antitussive) plants reported the most potent effect for black seed and flaxseed on coughs induced by sulfur dioxide, and said only a few clinical studies of medicinal plants for cough exist.

The mechanism proposed for the cough-suppressing effect is reduced airway sensory nerve hyper-excitability (the C-fiber and Adelta-fiber neurons that initiate the cough reflex). There may also be a TRPV1 receptor desensitization component — thymoquinone has been shown to interact with TRPV1, the sensory neuron channel responsible for the burning sensation of capsaicin and the cough response to irritant stimuli.

For acute bronchitis, people who use the traditional Yemeni black-seed-and-honey preparation report mild benefit for symptom severity and duration. No controlled trial of it was found. What people describe:

The traditional home use is 1 teaspoon black seed oil with 1 teaspoon raw honey, taken twice daily, started at the first sign of respiratory illness and continued until symptoms clear, alongside fluids, rest and the standard supportive measures.

Back to Table of Contents

Chronic Obstructive Pulmonary Disease Evidence and Limitations

Chronic obstructive pulmonary disease (COPD) is mechanistically distinct from asthma — chronic obstructive pulmonary disease involves neutrophilic rather than eosinophilic inflammation, with parenchymal destruction (emphysema) and chronic mucus hypersecretion (chronic bronchitis) as the dominant pathologies. The mast cell stabilization and Th2-suppression mechanisms that work in asthma are less directly relevant to chronic obstructive pulmonary disease.

However, a randomized trial in chronic obstructive pulmonary disease has reported some benefit:

Black seed has been tested only as an add-on in this disease — smoking cessation, inhaled bronchodilators, pulmonary rehabilitation, and (in advanced disease) supplemental oxygen remain the foundation of chronic obstructive pulmonary disease care. Black seed may have adjunct utility for the inflammatory component, particularly in patients with the asthma-COPD overlap syndrome (ACOS) where Th2 inflammation plays a larger role.

Back to Table of Contents

Doses in the Trials and in Traditional Use

Back to Table of Contents

Cautions and Limits

For the broader asthma management framework, see Asthma and Pulmonology.

Back to Table of Contents

Key Research Papers

  1. Boskabady MH, Javan H, Sajady M, Rakhshandeh H (2007). The possible prophylactic effect of Nigella sativa seed extract in asthmatic patients. Fundamental & Clinical Pharmacology 21(5):559-66. — PubMed PMID: 17868210
  2. Salem AM, Bamosa AO, Qutub HO, Gupta RK, Badar A, Elnour A, Afzal MN (2017). Effect of Nigella sativa supplementation on lung function and inflammatory mediators in partly controlled asthma: a randomized controlled trial. Annals of Saudi Medicine 37(1):64-71. — PubMed PMID: 28151459
  3. Koshak A, Wei L, Koshak E, Wali S, Alamoudi O, Demerdash A, Qutub M, Pushparaj PN, Heinrich M (2017). Nigella sativa Supplementation Improves Asthma Control and Biomarkers: A Randomized, Double-Blind, Placebo-Controlled Trial. Phytotherapy Research 31(3):403-409. — PubMed PMID: 28093815
  4. Koshak A, Koshak E, Heinrich M (2017). Medicinal benefits of Nigella sativa in bronchial asthma: A literature review. Saudi Pharmaceutical Journal 25(8):1130-1136. — PubMed PMID: 30166900
  5. Boskabady MH, Mohsenpoor N, Takaloo L (2010). Antiasthmatic effect of Nigella sativa in airways of asthmatic patients. Phytomedicine 17(10):707-13. — PubMed PMID: 20149611
  6. Saadat S, Shakeri F, Boskabady MH (2018). Comparative Antitussive Effects of Medicinal Plants and Their Constituents. Alternative Therapies in Health and Medicine 24(4):36-49. — PubMed PMID: 29332022
  7. Nikakhlagh S et al. (2011). Herbal treatment of allergic rhinitis: the use of Nigella sativa. American Journal of Otolaryngology. — PubMed PMID: 20947211
  8. Alsamarai AM et al. (2014). Evaluation of topical black seed oil in the treatment of allergic rhinitis. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. — PubMed PMID: 23855426
  9. Boskabady MH, Shirmohammadi B, Jandaghi P, Kiani S (2004). Possible mechanism(s) for relaxant effect of aqueous and macerated extracts from Nigella sativa on tracheal chains of guinea pig. BMC Pharmacology 4:3. — PubMed PMID: 15070429
  10. Chakravarty N (1993). Inhibition of histamine release from mast cells by nigellone. Annals of Allergy. — PubMed PMID: 7680846
  11. Kalus U et al. (2003). Effect of Nigella sativa (black seed) on subjective feeling in patients with allergic diseases. Phytotherapy Research. — PubMed PMID: 14669258
  12. Keyhanmanesh R et al. (2010). Effect of thymoquinone, the main constituent of Nigella sativa, on tracheal responsiveness and white blood cell count in lung lavage of sensitized guinea pigs. Planta Medica. — PubMed PMID: 19711253
  13. Al-Azzawi MA, AboZaid MMN, Ibrahem RAL, Sakr MA (2020). Therapeutic effects of black seed oil supplementation on chronic obstructive pulmonary disease patients: A randomized controlled double blind clinical trial. Heliyon 6(8):e04711. — PubMed PMID: 32904114
  14. Abumadini MM, Ahmad S, AlYahya W, Amalraj C, AlGindan Y (2025). Clinical Uses of Nigella Sativa in Pediatrics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Pediatric Pharmacology and Therapeutics 30(5):580-592. — PubMed PMID: 41112345
  15. Gilani AH et al. (2004). A review of medicinal uses and pharmacological activities of Nigella sativa. Pakistan Journal of Biological Sciences 7:441-451. — doi:10.3923/pjbs.2004.441.451

PubMed Topic Searches

  1. PubMed: Nigella sativa asthma clinical trials
  2. PubMed: Thymoquinone bronchodilation
  3. PubMed: Nigella sativa allergic rhinitis
  4. PubMed: Nigella sativa mast cell / histamine
  5. PubMed: Thymoquinone lung inflammation / eosinophil

Back to Table of Contents

Connections

Back to Table of Contents